StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $45.00 price target on shares of Moleculin Biotech in a research note on Thursday, December 14th. Get […]

Related Keywords

Walterv Klemp , , Moleculin Biotech Inc , Moleculin Biotech Company Profile , Securities Exchange Commission , Charles Schwab Investment Management Inc , Renaissance Technologies , Citadel Advisors , Armistice Capital , Atticus Wealth Management , Moleculin Biotech , Free Report , Exchange Commission , Wealth Management , Schwab Investment Management , Get Free Report , Moleculin Biotech Daily ,